Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men?
Q: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men? Evidence-based answer: Yes. Quadrivalent human papillomavirus (qHPV) vaccine reduces rates of anal intraepithelial neoplasia (AIN) by 50% to 54%, and persistent anal infection by 59%, associated with the 4 types of HPV in the vaccine (6, 11, 16, and 18) in young men who have sex with men (MSM); it also reduces external genital lesions by 66%, and persistent HPV infection associated with the same 4 HPV types by 48 to 59% in all young men, heterosexual men, and MSM (strength of recommendation [SOR]: B, randomized, placebo-controlled trials [RCTs]). In addition, the vaccine is associated with a 50% to 55% decrease in recurrent high-grade AIN and anogenital condylomata in older MSM (SOR: B, cohort studies).
Journal of Family Practice, 64(9) 2015: 581-583 .
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.